To determine whether targeting HSP27 had differential effects in the absence or presence of SPARC, C1.1 GFP- and H2 SPARC-GFP-expressing glioma cells were treated with control or HSP27 siRNAs. The gene discussed is SPARC; the disease is central nervous system cancer.